|
|
||
 |
||
 |
||
We’re always seeking stories to promote NY’s diverse bioscience community. Please contact Deborah Flack by e-mail with your suggestions or call |
||
 |
||
| NY Loves Bio is coordinated by the New York State Economic Development Council with statewide support from leading bio advocates in industry, academia, government agencies, and local and regional economic development organizations. Together, we’re working to promote New York globally as a thriving center for life science research and commerce. | ||
|
Population Diagnostics Inc. (PDx), founded in 2007, is a molecular diagnostics and personalized medicine company whose central objectives are to develop DNA-based pre-symptomatic/early detection tests for autism, diabetes, Alzheimers, Parkinsons and other common diseases; and companion tests which predict the efficacy and safety of a drug prior to its administration. The company's technology also enables pharmaceutical companies to identify novel biological pathways for drug discovery. Finally, the technology empowers cytogeneticists to better classify mutations as benign or pathological in patients with an unknown disease etiology. PDx has developed a rapid, systematic and cost effective method for the discovery and validation of causative mutations (biomarkers) for any complex disease or any drug cohort. The company's core technology is the essential tool for the rational interpretation of the human genome, a prerequisite for revealing mutations with an unprecedented level of medical relevance. Causative is underscored as PDx's defining attribute because the clinical value of a causative biomarker is never in doubt when used as the key ingredient of a predictive test. Such biomarkers represent the highest level of certainty that a genetic condition is present or will eventually develop in a patient. 
Rheonix has developed an in vitro diagnostic device that not only delivers on the decade's long promise of microfluidic analysis for improving health, but also provides a platform that will enhance personalized medicine. This privately held in vitro diagnostics systems company, located in Ithaca, designs, develops, manufactures and markets fully-integrated microfluidic systems for molecular analysis in the clinical and industrial markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. These easy-to-use systems integrate on a single chip a number of complicated and time-intensive steps, including sample preparation, amplification and endpoint detection, which enable the analysis of complex biological samples on its proprietary cartridges. Through its strong chemistry, engineering and fabrication capabilities, the company is focusing on those applications where scale and rapid molecular testing is particularly important, such as near-patient and point-of-care identification of infectious disease; real-time sexually transmitted disease detection in the clinical market; and food, agricultural, and environmental testing in the industrial market. Rheonix has validated, expanded and begun optimization of the first product based on the technology platform in actual clinical settings for multiple indications including avian influenza virus (AIV); human papillomavirus (HPV); human immunodeficiency virus (HIV); and beta thalassemia. 